In vitro activity of immunosuppressive agents against Cryptococcus neoformans

Enferm Infecc Microbiol Clin (Engl Ed). 2022 Feb;40(2):86-88. doi: 10.1016/j.eimce.2020.09.007.

Abstract

Introduction: Infections caused by Cryptococcus neoformans are a major cause of fungal mortality in HIV-infected/AIDS patients and in those receiving organ transplants. We evaluated the in vitro activity of tacrolimus and cyclosporine in combination with amphotericin B and fluconazole against C. neoformans.

Methods: MICs were determined against a total of 30 clinical isolates of C. neoformans by the microdilution method following the CLSI M27-A3 guidelines and by the checkerboard method.

Results: Tacrolimus and cyclosporine A showed in vitro activity against cryptococcal isolates. The combination of amphotericin B with cyclosporine A or tacrolimus was synergistic against 90% and 30% of isolates, respectively. Synergism was also observed with the combination of fluconazole with cyclosporine A or tacrolimus, against 70% and 20% of isolates, respectively.

Conclusions: The synergistic interactions between the calcineurin inhibitors and antifungal drugs against C. neoformans isolates, could potentially have a role in devising novel therapeutic strategies for this opportunistic mycosis.

Keywords: Amphotericin B; Anfotericina B; Ciclosporina A; Cryptococcus spp.; Cyclosporine A; Sinergia; Synergism; Tacrolimus.

MeSH terms

  • Antifungal Agents / pharmacology
  • Antifungal Agents / therapeutic use
  • Cryptococcosis* / drug therapy
  • Cryptococcus neoformans*
  • Drug Synergism
  • Fluconazole / pharmacology
  • Fluconazole / therapeutic use
  • Humans
  • Immunosuppressive Agents / pharmacology
  • Immunosuppressive Agents / therapeutic use

Substances

  • Antifungal Agents
  • Immunosuppressive Agents
  • Fluconazole